Allergan PLC acquires autoimmune-focused Vitae for $639mm

15:41 EDT 15 Sep 2016 | Elsevier Business Intelligence

Allergan PLC acquired public biotech Vitae Pharmaceuticals Inc. (computational drug design), paying $21 per share (a 175% premium) in cash for all Vitae outstanding shares, valuing the transaction at $639mm.

Original Article: Allergan PLC acquires autoimmune-focused Vitae for $639mm


More From BioPortfolio on "Allergan PLC acquires autoimmune-focused Vitae for $639mm"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...